Valuation: ACLS THER

Market Cap 888M 769M 717M 660M 1.25B 84.46B 1.26B 8.43B 3.31B 42.26B 3.34B 3.26B 140B P/E 2026 *
-9.8x
P/E 2027 * -7.99x
Enterprise Value 753M 652M 608M 559M 1.06B 71.57B 1.07B 7.14B 2.8B 35.81B 2.83B 2.76B 119B EV / Sales 2026 *
132x
EV / Sales 2027 * 142x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-01-16
President 67 2024-11-17
Director of Finance/CFO 39 2022-12-31
Director TitleAgeSince
Chairman 56 2022-12-31
Director/Board Member 50 2014-08-31
Director/Board Member 59 2016-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+4.35%+16.60%+58.11%+95.21% 64.9B
+2.30%+2.63%+31.51%+73.31% 54.05B
+0.91%-0.83%-17.01%-13.43% 23.16B
+0.27%-3.98%-11.28%+350.30% 21.46B
+1.87%+9.47%+30.87%-5.63% 21.25B
+0.62%+3.31%+38.34%-25.03% 17.94B
+9.88%+23.61%+222.87%+385.49% 17.03B
+3.29%+5.61%+21.01%+636.23% 14.99B
+1.25%+2.48%+51.36%+179.72% 14.25B
Average +2.75%+5.03%+47.31%+186.24% 27.67B
Weighted average by Cap. +2.90%+5.90%+44.27%+142.31%

Financials

2026 *2027 *
Net sales 5.71M 4.95M 4.61M 4.24M 8.01M 543M 8.1M 54.2M 21.27M 272M 21.46M 20.98M 900M 5.36M 4.64M 4.33M 3.98M 7.51M 510M 7.6M 50.84M 19.95M 255M 20.13M 19.68M 844M
Net income -84.78M -73.43M -68.45M -62.96M -119M -8.06B -120M -804M -316M -4.03B -318M -311M -13.36B -103M -88.79M -82.77M -76.12M -144M -9.75B -145M -973M -382M -4.88B -385M -377M -16.15B
Net Debt -136M -117M -109M -101M -190M -12.89B -192M -1.29B -505M -6.45B -509M -498M -21.37B -125M -108M -101M -92.75M -175M -11.88B -177M -1.18B -465M -5.94B -469M -459M -19.68B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-